Table 2 Proportional distribution of hospitalized patients with Covid-19 Pneumonia according to the treatment received
Variables | Treatment | Total patients (n = 301) | Pearson’s Chi-Squared p-value | ||
|---|---|---|---|---|---|
Corticosteroids (n = 95) | Corticosteroids AndColchicine (n = 145) | Without Corticosteroids (n = 61) | |||
Hydroxychloroquine and Lopinavir/Ritonavir | 8 (8.4%) | 0 (0%) | 9 (14.8%) | 17 (5.6%) | < 0.001 |
Other Antibiotics | 95 (100%) | 137 (94.5%) | 40 (65.8%) | 272 (90.4%) | < 0.001 |
Ceftriaxone | 64 (67.4%) | 112 (77.2%) | 29 (47.5%) | 205 (68.1%) | 0.002 |
Azithromycin | 75 (78.9%) | 122 (84.1%) | 22 (36.1%) | 219 (72.8%) | < 0.001 |
Tocilizumab | 0 (0%) | 1 (0.7%) | 0 (0%) | 1 (0.3%) | 0.58 |
Dexamethasone | 91 (95.8%) | 133 (91.7%) | 0 (0%) | 224 (74.4%) | < 0.001 |
ICU Admission | 45 (47.4%) | 48 (33.1%) | 12 (19.8%) | 105 (34.9%) | 0.002 |
No Data | 1 (1.1%) | 2 (1.4%) | 0 (0%) | 3 (0.9%) | |
ConventionalOxygen therapy | 91 (95.8%) | 129 (88.9%) | 45 (73.8%) | 265 (88%) | 0.002 |
No data | 0 (0%) | 2 (1.4%) | 0 (0%) | 2 (0.7%) | |
High-flow nasal canula | 62 (65.3%) | 62 (42.8%) | 12 (19.7%) | 136 (45.2%) | < 0.001 |
No data | 1 (1.1%) | 3 (2.1%) | 0 (0%) | 4 (1.3%) | |
Mechanical ventilation | 28 (29.5%) | 26 (17.9%) | 3 (4.9%) | 57 (18.9%) | < 0.001 |
No data | 1 (1.1%) | 2 (1.4%) | 0 (0%) | 3 (0.9%) | |